Palifosfamide Tris and Doxorubicin + Doxorubicin
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Aug 1, 2008 → Apr 1, 2014
NCT ID
NCT00718484About Palifosfamide Tris and Doxorubicin + Doxorubicin
Palifosfamide Tris and Doxorubicin + Doxorubicin is a phase 2 stage product being developed by Alaunos Therapeutics for Soft Tissue Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00718484. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00718484 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Soft Tissue Sarcoma